ClinicalTrials.gov record
Terminated Phase 1 Interventional

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT02914938

Public ClinicalTrials.gov record NCT02914938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

Study identification

NCT ID
NCT02914938
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
MEI Pharma, Inc.
Industry
Enrollment
97 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2016
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Last update posted
May 8, 2023

2016 – 2023

United States locations

U.S. sites
23
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
University of Arizona Tucson Arizona 85724
Compassionate Care Corona California 92708
Sylvester Comprehensive Cancer Center (Univ of Miami School of Med) Miami Florida 33136
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114
Dana Farber Boston Massachusetts 02215
Memorial Sloan Kettering Basking Ridge New Jersey 07920
Memorial Sloan Kettering Middletown New Jersey 07748
Memorial Sloan Kettering Montvale New Jersey 07645
Memorial Sloan Kettering Commack New York 11725
Memorial Sloan Kettering Harrison New York 10604
NYU Langone Laura & Isaac - Perlmutter Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Stony Brook Stony Brook New York 11794
Memorial Sloan Kettering Uniondale New York 11553
Cleveland Clinic Cleveland Ohio 44195
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Vanderbilt Nashville Tennessee 37240
University of Southwestern Medical Center Dallas Texas 75390
MD Anderson Cancer Center Houston Texas 77030
Swedish Cancer Institute Edmonds Washington 98026
Swedish Cancer Institute Issaquah Washington 98029
Swedish Cancer Center Seattle Washington 98104
Carbone Cancer Center Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02914938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 8, 2023 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02914938 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →